Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
38 results
Cited 1 times since 2015 (0.1 per year) source: EuropePMC
Cardiovascular and interventional radiology, Volume 38, Issue 6, 24 4 2015, Pages 1674-1675 Testicular Embolism After Endovascular Aneurysm Repair: A Rare Complication of Endovascular Repair of Abdominal Aortic Aneurysms. Vervoort M, Hoencamp R, Eefting D
Cited 2 times since 2014 (0.2 per year) source: EuropePMC
Cardiovascular and interventional radiology, Volume 38, Issue 3, 22 4 2014, Pages 600-605 Thromboembolic complications after Zenith® Low Profile Endovascular Graft for infrarenal abdominal aneurysms. Urlings TA, de Vries AC, de Mol van Otterloo JC, Eefting D, van der Linden E
Purpose: The purpose of this study was to objectify and evaluate risk factors for thromboembolic complications after treatment with a Zenith(®) Low Profile Endovascular Graft (Zenith LP). Results were compared with those in the recent literature on endovascular aortic repair (EVAR) and with the thromboembolic complications in the patient group treated with a Zenith Flex Endovascular Graft in our institute in the period before the use of the Zenith LP. Materials and methods: All consecutive patie... Abstract
Cited 6 times since 2014 (0.6 per year) source: EuropePMC
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, Volume 47, Issue 5, 20 3 2014, Pages 479-486 Differences in mortality, risk factors, and complications after open and endovascular repair of ruptured abdominal aortic aneurysms. von Meijenfeldt GC, Ultee KH, Eefting D, Hoeks SE, ten Raa S, Rouwet EV, Hendriks JM, Verhagen HJ, Bastos Goncalves FM
Objective/background: Endovascular aneurysm repair (EVAR) for ruptured abdominal aortic aneurysm (rAAA) has faced resistance owing to the marginal evidence of benefit over open surgical repair (OSR). This study aims to determine the impact of treatment modality on early mortality after rAAA, and to assess differences in postoperative complications and long-term survival. Methods: Patients treated between January 2000 and June 2013 were identified. The primary endpoint was early mortality. Second... Abstract
Cited 2 times since 2013 (0.2 per year) source: EuropePMC
Cardiovascular and interventional radiology, Volume 38, Issue 2, 19 3 2013, Pages 498-500 Endovascular salvage of a false aneurysm of the posterior tibial artery caused by a stab from a stingray. van Helden EJ, Eefting D, Florie J, Verhagen HJ, Moelker A
Cited 7 times since 2013 (0.6 per year) source: EuropePMC
The Journal of cardiovascular surgery, Volume 54, Issue 1 Suppl 1, 1 1 2013, Pages 47-53 Ruptured AAA: state of the art management. Eefting D, Ultee KH, Von Meijenfeldt GC, Hoeks SE, ten Raa S, Hendriks JM, Bastos Goncalves F, Verhagen HJ
Since its introduction more than two decades ago, endovascular aneurysm repair (EVAR) has become the primary choice for elective treatment of abdominal aortic aneurysms (AAA) in many medical centers. The (dis)advantages, including 30-day mortality and long-term survival, of both open and endovascular elective AAA repair have been studied extensively, including four randomized trials. On the contrary, the survival benefit of EVAR for ruptured AAAs is not as well established as in elective situati... Abstract
Cited 15 times since 2010 (1.1 per year) source: EuropePMC
Cardiovascular research, Volume 88, Issue 2, 17 3 2010, Pages 367-375 A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Eefting D, Seghers L, Grimbergen JM, de Vries MR, de Boer HC, Lardenoye JW, Jukema JW, van Bockel JH, Quax PH
Aims: Matrix metalloproteinases (MMP) and plasminogen activator (PA)/plasmin-mediated proteolysis, especially at the cell surface, play important roles in matrix degeneration and smooth muscle cell migration, which largely contributes to vein graft failure. In this study, a novel hybrid protein was designed to inhibit both protease systems simultaneously. MMP and plasmin activity were inhibited at the cell surface by this hybrid protein, consisting of the receptor-binding amino-terminal fragment... Abstract
Cited 12 times since 2009 (0.8 per year) source: EuropePMC
Journal of vascular surgery, Volume 51, Issue 2, 24 4 2009, Pages 429-437 In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor. Eefting D, de Vries MR, Grimbergen JM, Karper JC, van Bockel JH, Quax PH
Background: Smooth muscle cell (SMC) migration and proliferation are important in the development of intimal hyperplasia, the major cause of vein graft failure. Proteases of the plasminogen activator (PA) system and of the matrix metalloproteinase (MMP) system are pivotal in extracellular matrix degradation and, by that, SMC migration. Previously, we demonstrated that inhibition of both protease systems simultaneously with viral gene delivery of the hybrid protein TIMP-1.ATF, consisting of the t... Abstract
Cited 27 times since 2009 (1.8 per year) source: EuropePMC
Journal of vascular surgery, Volume 50, Issue 1, 1 1 2009, Pages 152-160 Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. Eefting D, Bot I, de Vries MR, Schepers A, van Bockel JH, Van Berkel TJ, Biessen EA, Quax PH
Objective: Inflammatory responses to vascular injury are key events in vein graft disease and accelerated atherosclerosis, which may result in bypass failure. The monocyte chemoattractant protein-1 (MCP-1)/CC-chemokine receptor (CCR)-2 pathway is hypothesized to play a central role. A murine model for vein graft disease was used to study the effect of local application of lentiviral short hairpin RNA (shRNA) targeted against CCR2. Methods: A venous interposition was placed into the carotid arter... Abstract
Cited 114 times since 2009 (7.4 per year) source: EuropePMC
The American journal of surgical pathology, Volume 33, Issue 1, 1 1 2009, Pages 50-57 Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors. Eefting D, Schrage YM, Geirnaerdt MJ, Le Cessie S, Taminiau AH, Bovée JV, Hogendoorn PC, EuroBoNeT consortium
The distinction between benign and malignant cartilaginous tumors of bone is one of the most difficult subjects in surgical pathology. The grading of chondrosarcoma also seems to vary considerably among pathologists. However, clinical management differs. The purpose of this study was (1) to investigate interobserver variability in histological diagnosis and grading of central cartilaginous tumors and (2) to assess the diagnostic value of defined histologic parameters in differentiating enchondro... Abstract
Cited 13 times since 2007 (0.8 per year) source: EuropePMC
Human gene therapy, Volume 18, Issue 9, 1 1 2007, Pages 861-869 Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA. Eefting D, Grimbergen JM, de Vries MR, van Weel V, Kaijzel EL, Que I, Moon RT, Löwik CW, van Bockel JH, Quax PH
For the successful application of RNA interference in vivo, it is desired to achieve (local) delivery of small interfering RNAs (siRNAs) and long-term gene silencing. Nonviral electrodelivery is suitable to obtain local and prolonged expression of transgenes. By intramuscular electrodelivery of a plasmid in which two opposing human polymerase III promoters (H1 and U6) drive the expression of siRNA constructs that form functional double-stranded siRNAs, in combination with in vivo bioluminescence... Abstract
Cited 90 times since 2007 (5.4 per year) source: EuropePMC
Arteriosclerosis, thrombosis, and vascular biology, Volume 27, Issue 11, 23 4 2007, Pages 2310-2318 Natural killer cells and CD4+ T-cells modulate collateral artery development. van Weel V, Toes RE, Seghers L, Deckers MM, de Vries MR, Eilers PH, Sipkens J, Schepers A, Eefting D, van Hinsbergh VW, van Bockel JH, Quax PH
Objective: The immune system is thought to play a crucial role in regulating collateral circulation (arteriogenesis), a vital compensatory mechanism in patients with arterial obstructive disease. Here, we studied the role of lymphocytes in a murine model of hindlimb ischemia. Methods and results: Lymphocytes, detected with markers for NK1.1, CD3, and CD4, invaded the collateral vessel wall. Arteriogenesis was impaired in C57BL/6 mice depleted for Natural Killer (NK)-cells by anti-NK1.1 antibodie... Abstract
Cited 40 times since 2007 (2.3 per year) source: EuropePMC
Heart (British Cardiac Society), Volume 93, Issue 8, 20 3 2007, Pages 922-927 Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Pires NM, Eefting D, de Vries MR, Quax PH, Jukema JW
Background: Drug-eluting stents (DES) have been introduced successfully in clinical practice to prevent post-angioplasty restenosis. Nevertheless, concerns about the safety of DES still exist. Objective: To investigate the vascular pathology and transcriptional responses to sirolimus and paclitaxel in a murine model for restenosis on underlying diseased atherosclerotic arteries. Methods: Atherosclerotic lesions were induced by placement of a perivascular cuff around the femoral artery of hyperch... Abstract
Cited 158 times since 2007 (9.1 per year) source: EuropePMC
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Volume 22, Issue 1, 1 1 2007, Pages 19-28 Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Löwik CW
Unlabelled: Sclerostin is an osteocyte-derived negative regulator of bone formation. It inhibits BMP-stimulated bone formation both in vitro and in vivo but has no direct effect on BMP signaling. Instead, sclerostin inhibits Wnt signaling that is required for BMP-stimulated osteoblastic differentiation. Introduction: Sclerostin is a member of the Dan family of glycoproteins of which many members have been reported to antagonize BMP activity. Sclerostin has been shown to inhibit BMP-stimulated bo... Abstract
Cited 25 times since 2006 (1.4 per year) source: EuropePMC
Genes and immunity, Volume 8, Issue 1, 23 4 2006, Pages 44-50 Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Monraats PS, Kurreeman FA, Pons D, Sewgobind VD, de Vries FR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Huizinga TW, Eefting D, Quax PH, Frants RR, van der Laarse A, van der Wall EE, Jukema JW
Genetic factors appear to be important in the process of restenosis after percutaneous coronary intervention (PCI), as well as in inflammation, a pivotal factor in restenosis. An important mediator in the inflammatory response is interleukin (IL)-10. Our aim was to study whether genetic variants in IL-10 predispose to the risk of restenosis. The GENetic DEterminants of Restenosis (GENDER) study included 3104 patients treated with successful PCI. Target vessel revascularization (TVR) was chosen a... Abstract
Cited 33 times since 2006 (1.9 per year) source: EuropePMC
Atherosclerosis, Volume 193, Issue 2, 7 1 2006, Pages 335-342 The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Eefting D, Schepers A, De Vries MR, Pires NM, Grimbergen JM, Lagerweij T, Nagelkerken LM, Monraats PS, Jukema JW, van Bockel JH, Quax PH
Objective: Inflammatory factors are thought to play a regulatory role in restenosis. Interleukin-10 (IL10) is an important anti-inflammatory cytokine with anti-atherogenic potentials. The aim of this study was to assess the effects of IL10 modulation on cuff-induced neointima formation in hypercholesterolemic APOE*3-Leiden mice. Methods: The involvement of IL10 in neointima formation was studied in a hypercholesterolemic mouse model of cuff-induced stenosis of the femoral artery by IL10 knocking... Abstract
Cited 33 times since 2006 (1.9 per year) source: EuropePMC
Vascular pharmacology, Volume 45, Issue 5, 22 4 2006, Pages 281-301 Murine models of myocardial and limb ischemia: diagnostic end-points and relevance to clinical problems. Madeddu P, Emanueli C, Spillmann F, Meloni M, Bouby N, Richer C, Alhenc-Gelas F, Van Weel V, Eefting D, Quax PH, Hu Y, Xu Q, Hemdahl AL, van Golde J, Huijberts M, de Lussanet Q, Struijker Boudier H, Couffinhal T, Duplaa C, Chimenti S, Staszewsky L, Latini R, Baumans V, Levy BI
Ischemic disease represents the new epidemic worldwide. Animal models of ischemic disease are useful because they can help us to understand the underlying pathogenetic mechanisms and develop new therapies. The present review article summarizes the results of a consensus conference on the status and future development of experimentation in the field of cardiovascular medicine using murine models of peripheral and myocardial ischemia. The starting point was to recognize the limits of the approach,... Abstract
Cited 88 times since 2006 (4.9 per year) source: EuropePMC
Arteriosclerosis, thrombosis, and vascular biology, Volume 26, Issue 9, 6 1 2006, Pages 2063-2069 Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Schepers A, Eefting D, Bonta PI, Grimbergen JM, de Vries MR, van Weel V, de Vries CJ, Egashira K, van Bockel JH, Quax PH
Objective: Because late vein graft failure is caused by intimal hyperplasia (IH) and accelerated atherosclerosis, and these processes are thought to be inflammation driven, influx of monocytes is one of the first phenomena seen in IH, we would like to provide direct evidence for a role of the MCP-1 pathway in the development of vein graft disease. Methods and results: MCP-1 expression is demonstrated in various stages of vein graft disease in a murine model in which venous interpositions are pla... Abstract
Cited 20 times since 2006 (1.1 per year) source: EuropePMC
Journal of vascular surgery, Volume 43, Issue 4, 1 1 2006, Pages 809-815 Short-term dexamethasone treatment inhibits vein graft thickening in hypercholesterolemic ApoE3Leiden transgenic mice. Schepers A, Pires NM, Eefting D, de Vries MR, van Bockel JH, Quax PH
Objective: The aim of this study was to assess whether the anti-inflammatory agent dexamethasone can inhibit vein graft thickening without the occurrence of serious side effects. Methods: Venous interposition grafting was performed in the common carotid artery of hypercholesterolemic ApoE3Leiden transgenic mice. Mice were treated with dexamethasone (0.15 mg.kg(-1).d(-1) orally), and after 28 days, vein graft thickening was quantified. Results: Treatment with dexamethasone resulted in a significa... Abstract